These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 10961881)
1. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Taube J; Halsall D; Baglin T Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881 [TBL] [Abstract][Full Text] [Related]
2. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893 [TBL] [Abstract][Full Text] [Related]
3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Aithal GP; Day CP; Kesteven PJ; Daly AK Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515 [TBL] [Abstract][Full Text] [Related]
4. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129 [TBL] [Abstract][Full Text] [Related]
5. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Topić E; Stefanović M; Samardzija M Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835 [TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in sensitivity to warfarin--Nature or nurture? Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010 [TBL] [Abstract][Full Text] [Related]
8. Major bleeding caused by warfarin in a genetically susceptible patient. Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436 [TBL] [Abstract][Full Text] [Related]
9. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Kealey C; Chen Z; Christie J; Thorn CF; Whitehead AS; Price M; Samaha FF; Kimmel SE Pharmacogenomics; 2007 Mar; 8(3):217-25. PubMed ID: 17324110 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of warfarin elimination and its clinical implications. Takahashi H; Echizen H Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725 [TBL] [Abstract][Full Text] [Related]
12. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083 [TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356 [TBL] [Abstract][Full Text] [Related]
14. CYP2C9 polymorphism and warfarin dose requirements. Daly AK; Day CP; Aithal GP Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680 [No Abstract] [Full Text] [Related]
15. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971 [TBL] [Abstract][Full Text] [Related]
16. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin]. Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757 [TBL] [Abstract][Full Text] [Related]
17. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498 [TBL] [Abstract][Full Text] [Related]
18. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898 [TBL] [Abstract][Full Text] [Related]
19. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Yamazaki H; Inoue K; Shimada T Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436 [TBL] [Abstract][Full Text] [Related]
20. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Redman AR Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]